HER-2/neu is overexpressed infrequently in patients with prostate carcinoma: Results from the California Cancer Consortium Screening Trial

Cancer

Volumn 94, Issue 10, 2002, Pages 2584-2589

  Lara Jr , Primo N ^a   Meyers, Frederick J ^a   Gray, Carl R ^a   Edwards, Regina Gandour ^a   Gumerlock, Paul H ^a   Kauderer, Caren ^a   Tichauer, Garrett ^a   Twardowski, Przemyslaw ^b   Doroshow, James H ^b   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

HER 2 neu, immunohistochemistry; Hormone refractory prostate carcinoma; Trastuzumab

Indexed keywords

ANTIGEN; DOCETAXEL; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SCREENING; CLINICAL TRIAL; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; SCORING SYSTEM; UNITED STATES;

AGED; AGED, 80 AND OVER; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2;

EID: 0037093826     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10526     Document Type: Article

References (36)

1. Cancer statistics 2002
2. Treatment options in androgen independent prostate cancer
3. The neu gene: An erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor
4. Transfected neu oncogene induces human prostate cancer metastasis
5. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
6. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
7. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis
8. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: Correlation with overall survival
9. Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients
10. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: Correlation with poor prognosis
11. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer
12. Expression of c-erbB-2 gene product in urinary bladder cancer
13. Comparison of HER-2/neu in prostate and breast carcinomas
14. Expression of c-erb b-2/neu proto-oncogene in human prostatic cancer tissues and cell lines
15. Overexpression of the Her-2/neu receptor tyrosine kinase confers androgen-independent prostate cancer growth
16. Her2neu expression and progression toward androgen independence in human prostate cancer
17. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma
18. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer
19. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas
20. HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization
21. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer
22. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
23. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients
24. Circulating tumor markers in breast cancer: Accepted utilities and novel prospects
25. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2)
26. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin™ pivotal trials
27. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescent in situ hybridrization (FISH)
28. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer
29. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarray
30. Expression of cerbB2 (HER-2/neu) oncoprotein in human prostatic carcinoma
31. Overexpression of HER2/neu in solid tumors: An immunohistochemical survey
32. Her 2 expression in prostate cancer
33. Evaluation of HER2 in prostate cancer by immunohistochemistry (IHC) with 2 different antigen retrieval techniques and fluorescent in situ hybridization (FISH)
34. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors
35. A Phase II trial of herceptin alone and with taxol for the treatment of prostate cancer
36. HER2 expression in androgen independent prostate cancer